Sakashita Mizuha, Mochizuki Shinichi, Sakurai Kazuo
Department of Chemistry and Biochemistry, The University of Kitakyushu, 1-1, Hibikino, Wakamatsu-ku, Kitakyushu, Fukuoka 808-0135, Japan.
Department of Chemistry and Biochemistry, The University of Kitakyushu, 1-1, Hibikino, Wakamatsu-ku, Kitakyushu, Fukuoka 808-0135, Japan.
Bioorg Med Chem. 2014 Oct 1;22(19):5212-9. doi: 10.1016/j.bmc.2014.08.012. Epub 2014 Aug 17.
Highly efficient drug carriers targeting hepatocyte is needed for treatment for liver diseases such as liver cirrhosis and virus infections. Galactose or N-acetylgalactosamine is known to be recognized and incorporated into the cells through asialoglycoprotein receptor (ASGPR) that is exclusively expressed on hepatocyte and hepatoma. In this study, we synthesized a galactose-modified lipid with aromatic ring with click chemistry. To make a complex with DNA, termed 'lipoplex', we prepared a binary micelle composed of cationic lipid; dioleoyltrimethylammoniumpropane (DOTAP) and galactose-modified lipid (D/Gal). We prepared lipoplex from plasmid DNA (pDNA) and D/Gal and examined the cell specificity and transfection efficiency. The lipoplex was able to interact with ASGPR immobilized on gold substrate in the quartz-crystal microbalance (QCM) sensor cell. The lipoplex induced high gene expression to HepG2 cells, a human hepatocellular carcinoma cell line, but not to A549 cells, a human alveolar adenocarcinoma cell line. The treatment with asialofetuin, which is a ligand for ASGPR and would work as a competitive inhibitor, before addition of the lipoplexes decreased the expression to HepG2 cells. These results indicate that D/Gal lipoplex was incorporated into HepG2 cells preferentially through ASGPR and the uptake was caused by galactose specific receptor. This delivery system to hepatocytes may overcome the problems for gene therapy and be used for treatment of hepatitis and hepatic cirrhosis.
治疗肝硬化和病毒感染等肝脏疾病需要高效的靶向肝细胞的药物载体。已知半乳糖或N - 乙酰半乳糖胺可通过仅在肝细胞和肝癌细胞上表达的去唾液酸糖蛋白受体(ASGPR)被识别并进入细胞。在本研究中,我们通过点击化学合成了一种带有芳香环的半乳糖修饰脂质。为了与DNA形成复合物,即“脂质体复合物”,我们制备了由阳离子脂质二油酰基三甲基铵丙烷(DOTAP)和半乳糖修饰脂质(D/Gal)组成的二元胶束。我们从质粒DNA(pDNA)和D/Gal制备了脂质体复合物,并检测了细胞特异性和转染效率。该脂质体复合物能够与石英晶体微天平(QCM)传感器细胞中固定在金基质上的ASGPR相互作用。脂质体复合物对人肝癌细胞系HepG2细胞诱导了高基因表达,但对人肺泡腺癌细胞系A549细胞则没有。在添加脂质体复合物之前用去唾液酸胎球蛋白(一种ASGPR的配体,可作为竞争性抑制剂)处理,降低了对HepG2细胞的表达。这些结果表明,D/Gal脂质体复合物优先通过ASGPR进入HepG2细胞,并且摄取是由半乳糖特异性受体引起的。这种向肝细胞的递送系统可能克服基因治疗的问题,并用于治疗肝炎和肝硬化。